MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 84 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $681,053 | -44.7% | 582,097 | +327.0% | 0.00% | – |
Q1 2024 | $1,232,306 | +56.1% | 136,317 | +87.7% | 0.00% | – |
Q4 2023 | $789,368 | -15.6% | 72,619 | -37.5% | 0.00% | – |
Q3 2023 | $935,418 | +31.5% | 116,201 | +77.3% | 0.00% | – |
Q2 2023 | $711,580 | -33.1% | 65,523 | -57.5% | 0.00% | – |
Q1 2023 | $1,063,697 | +58.9% | 154,159 | -8.3% | 0.00% | – |
Q4 2022 | $669,321 | +44196.6% | 168,171 | -26.0% | 0.00% | – |
Q3 2022 | $1,511 | +586.8% | 227,219 | +398.5% | 0.00% | – |
Q2 2022 | $220 | -100.0% | 45,584 | -71.0% | 0.00% | – |
Q1 2022 | $1,468,000 | -18.4% | 156,949 | +3.5% | 0.00% | – |
Q4 2021 | $1,800,000 | -33.8% | 151,569 | -36.6% | 0.00% | -100.0% |
Q3 2021 | $2,721,000 | -35.4% | 239,125 | +1.8% | 0.00% | 0.0% |
Q2 2021 | $4,214,000 | +18.3% | 234,872 | +2.1% | 0.00% | 0.0% |
Q1 2021 | $3,561,000 | +363.7% | 229,994 | +265.2% | 0.00% | – |
Q4 2020 | $768,000 | +88.2% | 62,976 | +98.5% | 0.00% | – |
Q3 2020 | $408,000 | – | 31,723 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 3,156,803 | $15,279,000 | 3.01% |
Lion Point Capital, LP | 3,684,622 | $18,959,000 | 2.16% |
Bleichroeder LP | 1,322,463 | $6,401,000 | 1.32% |
Bain Capital Life Sciences Investors, LLC | 1,431,058 | $6,926,000 | 0.81% |
683 Capital Management, LLC | 1,900,000 | $9,196,000 | 0.65% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 3,510,831 | $16,992,000 | 0.65% |
Granite Point Capital Management, L.P. | 472,056 | $2,285,000 | 0.58% |
Stonepine Capital Management, LLC | 242,327 | $1,173,000 | 0.55% |
Avoro Capital Advisors LLC | 3,150,000 | $15,246,000 | 0.30% |
Artal Group S.A. | 1,000,000 | $4,840,000 | 0.26% |